Discontinuation report LARTRUVO
Report ID | 117642 |
Drug Identification Number | 02469227 |
Brand name | LARTRUVO |
Common or Proper name | OLARATUMAB |
Company Name | ELI LILLY CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | OLARATUMAB |
Strength(s) | 500MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | I Vial , 500 MG / 50 ML |
ATC code | L01XC |
ATC description | |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2020-06-04 |
Actual discontinuation date | 2020-06-04 |
Remaining supply date | 2020-06-04 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-06-15 | English | Compare |
v2 | 2020-06-15 | French | Compare |
Showing 1 to 2 of 2